Demographic and clinical parameters
| Variable | TLE, n=74 | LTLE, n=43 | RTLE, n=31 | P |
| Age§ | 34.5 (12) | 34.7 (SD 12) | 32.1 (SD 10) | p=0.1* |
| Female gender, % | 55.8 | 44.0 | 67.0 | p=0.06‡ |
| Age at first seizure§ | 15.3 (10.7) | 15.4 (SD 10) | 13.8 (SD 9) | p=0.3* |
| Weekly frequency of seizures¶ | 1 (5–3) | 1 (0.75–5) (5.8) | 1 (0.5–2) | p=0.1* |
| Self-reported seizure predominance, N (%) | ||||
| No predominance | 56.7 | 58.1 | 54.8 | p=0.8‡ |
| Sleep predominance | 13.5 | 11.6 | 16.1 | |
| Wakefulness predominance | 16.2 | 18.6 | 12.9 | |
| Only during wakefulness | 13.5 | 11.6 | 16.1 | |
| Antiseizure drugs, N (%) | ||||
| One drug | 10.8 | 9.3 | 12.9 | p=0.4‡ |
| Two drugs | 45.9 | 41.9 | 51.6 | |
| Three drugs | 32.4 | 39.5 | 22.6 | |
| Four drugs | 10.8 | 9.3 | 12.9 | |
| Benzodiazepines/fenobarbital use | 37.8 | 41.9 | 32.3 | p=0.4† |
| MRI findings (%) | ||||
| Normal MRI | 23.0 | 9.4 | 29.3 | p=0.1‡ |
| Mesial sclerosis | 36.5 | 37.7 | 17.1 | |
| Cortical dysplasia | 10.8 | 5.7 | 12.2 | |
| Low grade tumour | 13.5 | 15.1 | 4.9 | |
| Chronic sequelae | 16.2 | 13.2 | 12.2 | |
*Unpaired T test.
†Fisher test.
‡χ2 test.
§Mean (standard deviation).
¶Median (IQR).
LTLE, left temporal lobe epilepsy; RTLE, right temporal lobe epilepsy; TLE, temporal lobe epilepsy.